#Dengue Testing Market demand

[mordormr]

Global Dengue Testing Market: Trends, Growth Drivers, and Future Opportunities

The Dengue Testing Market is projected to be valued at USD 436.19 million in 2024, with expectations to grow to USD 540.20 million by 2029, reflecting a compound annual growth rate (CAGR) of 4.37% over the forecast period from 2024 to 2029.

Key Market Drivers in the Dengue Testing Industry

The dengue testing market is expanding due to several key factors:

Increasing Disease Prevalence: The spread of dengue has extended into new territories, including urban areas in Europe and North America, leading to increased awareness and demand for diagnostic solutions.

Government Initiatives and Health Campaigns: Numerous governments and health organizations have launched initiatives to enhance diagnostic capabilities and raise awareness about dengue prevention and early diagnosis. Such efforts, coupled with collaborations with diagnostic companies, have spurred market growth.

Advancements in Diagnostic Technologies: Diagnostic technologies have evolved, making testing more accessible, reliable, and rapid. PCR (Polymerase Chain Reaction), ELISA (Enzyme-linked Immunosorbent Assay), and point-of-care rapid tests are becoming the industry standard for dengue detection, catering to various healthcare settings.

Emerging Trends in the Dengue Testing Market

The dengue testing industry is embracing innovative technologies and strategies, which are redefining the diagnostics landscape:

Rise of Point-of-Care Testing (POCT): Rapid point-of-care tests for dengue are in high demand as they offer near-immediate results, enabling timely diagnosis and treatment in areas with limited access to full laboratory services.

Multiplexed Diagnostics: Multi-pathogen testing kits, which can diagnose multiple vector-borne diseases, such as dengue, Zika, and chikungunya, are becoming more popular. This approach is particularly beneficial in regions where multiple diseases co-circulate.

Telemedicine and Remote Diagnostics: With the rise of digital health solutions, the dengue testing industry is exploring telemedicine tools for remote diagnostics. This trend is expected to increase testing accessibility in underserved areas.

Artificial Intelligence (AI) and Machine Learning: AI-driven diagnostic tools can predict dengue outbreaks and assist with patient triage, offering a significant boost in regions prone to recurrent outbreaks.

Challenges Facing the Dengue Testing Industry

While the dengue testing market is expanding, several challenges persist:

Seasonality of Dengue Outbreaks: Dengue is often seasonal, peaking during rainy months, which can lead to fluctuating demand.

Resource Constraints in Developing Regions: Lack of infrastructure and trained professionals in low-income regions hampers the adoption of advanced diagnostic tools, limiting the market's reach.

Risk of Cross-Reactivity in Tests: Dengue diagnostic tests can sometimes cross-react with other flaviviruses like Zika, leading to false positives or negatives, which remains a challenge in diagnostics.

Future Outlook and Growth Opportunities

The future of the dengue testing market looks promising, with a projected compound annual growth rate (CAGR) of approximately 6-7% over the next decade. Several factors will drive this growth:

Investment in Research and Development: Continued investment in R&D for faster, more accurate, and cost-effective diagnostic solutions will be crucial in meeting the demand for dengue testing.

Expansion of Testing in Emerging Markets: Emerging markets in Asia, Africa, and Latin America are expected to see increased dengue testing infrastructure, supported by both public health organizations and private companies.

Adoption of Advanced Technologies: As artificial intelligence, cloud-based diagnostics, and data analytics become more integrated into healthcare, their application in dengue diagnosis could transform the industry. Predictive analytics may assist in outbreak management, while digital diagnostic platforms could improve access to quality testing.

Conclusion

The global dengue testing industry is a rapidly evolving market with immense potential, fueled by increasing cases, technological advancements, and the commitment of healthcare stakeholders to combat vector-borne diseases. The future of dengue testing looks geared towards affordability, accuracy, and accessibility, especially for at-risk populations in endemic regions. As the world becomes more interconnected and urbanized, proactive and innovative diagnostic solutions will be crucial in managing the ongoing dengue burden effectively.

[lovelypol]

Zika Virus Testing Market to Expand to $4.3 Billion by 2033 with a 5.8% CAGR

Zika Virus Testing Market : Zika virus testing is a critical tool in the global fight against vector-borne diseases. Accurate and timely diagnosis helps identify infections early, enabling swift treatment and effective containment strategies. Modern Zika testing methods, such as molecular diagnostics (RT-PCR) and serological tests, provide precise results, allowing healthcare providers to differentiate Zika from other similar infections like dengue and chikungunya. This innovation is particularly crucial for pregnant women, as early detection can significantly reduce the risk of congenital Zika syndrome in newborns.

To Request Sample Report : https://www.globalinsightservices.com/request-sample/?id=GIS32570 &utm_source=SnehaPatil&utm_medium=Article

As outbreaks remain a public health concern, the demand for rapid, cost-effective, and portable testing solutions is driving innovation in the field. Point-of-care devices and advanced laboratory techniques are empowering communities to monitor and manage outbreaks effectively. These advancements in testing are not just about disease control — they represent a proactive step toward safeguarding global health and ensuring that vulnerable populations receive timely care.

#ZikaVirus #VirusTesting #PublicHealth #DiseasePrevention #DiagnosticTools #GlobalHealth #HealthcareInnovation #RT-PCR #SerologicalTesting #VectorBorneDiseases #PregnancyHealth #RapidTesting #PointOfCare #InfectiousDiseases #HealthTech

[tbrc34]

"A New Era of Arbovirus Testing: Navigating Challenges and Opportunities (2024-2033)"

Arbovirus Testing Market : Arbovirus testing is becoming increasingly essential as global health organizations tackle the rising threat of mosquito-borne diseases like Zika, dengue, and chikungunya. Rapid and accurate testing allows for early detection, enabling timely responses to prevent outbreaks. Laboratories and healthcare providers are leveraging advanced diagnostic technologies to identify these viruses, helping protect communities from potentially severe consequences such as neurological complications and birth defects.

Download PDF Sample Report@https://www.globalinsightservices.com/request-sample/GIS26941/?utm_source=SnehaPatil-Article

With climate change expanding the range of mosquito habitats, the demand for efficient arbovirus testing is on the rise. Public health efforts are increasingly focused on strengthening surveillance systems and improving diagnostic accuracy. Innovations in testing, including PCR and serological methods, are making it possible to track and contain the spread of these viruses, safeguarding both local and global populations.

Relevant Link : https://linkewire.com/2024/10/01/corpectomy-system-market-to-revolutionize-spine-surgery-2024-2033-outlook/

#ArbovirusTesting #PublicHealth #InfectiousDiseases #MosquitoBorneIllnesses #DiseasePrevention #ZikaVirus #DengueFever #ViralDiagnostics #GlobalHealth #Epidemiology

[ashwetu]

Meticulous Research® Unveils New Report: Africa IVD Market Poised to Reach $1.65 Billion by 2031

Meticulous Research®, a global leader in market research and consulting, has released a new report titled ‘Africa IVD Market Size, Share, Forecast & Trends Analysis by Offering, Technology (Immunoassay, PoC, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoCT), End User – Forecast to 2031.’ According to the latest findings, the Africa in vitro diagnostics (IVD) market is projected to grow at a compound annual growth rate (CAGR) of 3.1%, reaching $1.65 billion by 2031.

Download Sample Report Here : https://www.meticulousresearch.com/download-samplereport/cp_id=5415

Market Growth Drivers and Challenges

The expansion of the Africa IVD market is driven by multiple factors, including the rising prevalence of chronic and infectious diseases, increased investments from IVD companies, growing demand for point-of-care (PoC) and rapid diagnostics, and a burgeoning geriatric population. Furthermore, supportive government initiatives aimed at bolstering Africa's healthcare sector and increasing healthcare expenditure are playing a significant role in the market's development.

However, market growth is being restrained by the high costs of advanced IVD products, variations in test results for rapid diagnostics, and the stringent regulatory requirements for high-complexity diagnostic tests. On the other hand, advancements in genomics and proteomics, heightened awareness of early diagnosis, and the increasing adoption of personalized medicine are expected to create significant opportunities for market players. Despite these promising trends, uneven access to healthcare and a shortage of trained healthcare professionals remain critical challenges.

Check complete table of contents with list of table and figures:

Market Segmentation and Key Insights

The report provides detailed insights into the market, segmented by offering, technology, application, diagnostic approach, and end user:

By Offering: The market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment is expected to grow at the highest CAGR of 3.3% during the forecast period, driven by increased diagnostic test volumes for infectious diseases, particularly malaria and tuberculosis, and various initiatives aimed at improving healthcare access across Africa.

By Technology: In 2024, the immunoassay/immunochemistry segment is projected to account for the largest market share at 34.5%. This is largely due to immunoassay technology's efficient and accurate diagnostics for highly prevalent diseases such as HIV, malaria, and dengue in Africa, along with its cost-effectiveness and continuous development of new biomarkers.

By Application: The infectious diseases segment is expected to dominate the market in 2024, fueled by the widespread prevalence of diseases like COVID-19, dengue, and HIV. Increasing awareness of diagnostic testing and the availability of low-cost rapid test kits are key factors driving this segment’s growth.

Quick Buy:  https://www.meticulousresearch.com/Checkout/47708335

By Diagnostic Approach: Point-of-care testing (PoCT) is projected to witness the highest growth during the forecast period, driven by the rising demand for immediate diagnostic results, especially in remote and underserved regions.

By End User: Hospitals and clinics are expected to grow at the highest CAGR between 2024 and 2031. Factors such as the increasing number of hospitalizations for chronic diseases, rising healthcare expenditure, and the willingness of hospitals to adopt advanced diagnostic tools are contributing to this growth.

Geographic Insights

The report also provides an in-depth analysis of various African countries, including South Africa, Nigeria, Egypt, Algeria, Morocco, Kenya, Tunisia, Côte d’Ivoire, Tanzania, Cameroon, and the Rest of Africa. South Africa is projected to grow at the highest CAGR of 8.3% during the forecast period. The growth in South Africa is driven by increased healthcare expenditure, expanded access to diagnostic tools through partnerships and collaborations, and favorable government policies aimed at enhancing healthcare infrastructure.

Competitive Landscape

Key players in the Africa IVD market include Abbott Laboratories (U.S.), Becton, Dickinson and

Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche

Ltd (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo

Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China). These industry leaders continue to invest in the region, driving innovation and expanding their presence in the African market.

Request  Sample PDF Copy Here:  https://www.meticulousresearch.com/request-samplereport/cp_id=5415

Key Questions Addressed in the Report:

What is the current revenue generated by IVD products in Africa?What are the projected growth rates for the Africa IVD market over the next 5–7 years?What are the key drivers, opportunities, and challenges affecting this market?Which market segments are generating the most traction in terms of offering, technology, and application?Which countries in Africa offer significant growth opportunities for market participants? Who are the leading players, and what products and strategies are they employing in the Africa IVD market?What recent developments are shaping the competitive landscape?

Contact Information

Meticulous Research®

Email: sales@meticulousresearch.com

Phone: +1-646-781-8004

LinkedIn: Connect with us

[globalinsightsservices]

Esoteric Testing Market to Witness Growth Acceleration During 2021-2033

Market Definition

Esoteric Testing involves the laboratory examination of uncommon molecules and substances that is not often done in a clinical laboratory. These tests are carried out when a doctor needs more comprehensive information regarding the patient’s health. To assess the outcome, a sophisticated device, materials, and specialist are needed.

Market Dynamics

The global esoteric testing market was valued at USD 21.4 billion in 2022 and it is anticipated to grow further up to USD 62.9 billion by 2032, at a CAGR of 11.4% during the forecast period.

To Know More@ https://www.globalinsightservices.com/reports/esoteric-testing-market/

Market Trends and Drivers

The growing geriatric population coupled with the increasing prevalence of chronic and infectious diseases and advancing esoteric DNA sequencing technologies in precision medicine, early diagnosis of cancer, and precision medicine are boosting the growth of the market. Globally, chronic diseases including diabetes, heart disease, and cancer are on the rise. Infectious disease prevalence is also rising at an alarming rate and includes diseases like Dengue, Hepatitis B, C, HIV, Malaria, Tuberculosis, and others. The knowledge of esoteric testing for the quick and accurate detection of certain disorders is growing. Esoteric tests’ improving technology is providing quicker results with improved sensitivity, detection limits, and efficacy. The market is expanding as a result of the rising use of esoteric DNA sequencing, NGS technologies, and whole genome sequencing in the early diagnosis of cancer, precision medicine, and personalized medicine.

Request Sample@ https://www.globalinsightservices.com/request-sample/GIS10283/?utm_id=1017

Research Objectives

Estimates and forecast the overall market size for the total market, across product, service type, type, end-user, and region

Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling

Identify factors influencing market growth and challenges, opportunities, drivers and restraints

Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates

Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities

Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market

To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements.

Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives

Request Customization@ https://www.globalinsightservices.com/request-customization/GIS10283/

Global Esoteric Testing Market Segmentation:

By Type

Infectious Diseases Testing

Endocrinology Testing

Oncology Testing

Genetics Testing

Toxicology Testing

Immunology Testing

Neurology Testing

Others

By Technology

Chemiluminescence Immunoassay

Enzyme-Linked Immunosorbent Assay

Mass Spectrometry

Real-Time PCR

DNA Sequencing

Flow Cytometry

Others

By End User

Independent & Reference Laboratories

Hospital Based Technologies

Research Scope

Scope – Highlights, Trends, Insights. Attractiveness, Forecast

Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others

Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain

Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments

Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis

Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis.

Buy your copy here@ https://www.globalinsightservices.com/checkout/single_user/GIS10283/

With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions

In-depth segmentation which can be customized as per your requirements

Free consultation with lead analyst of the report

Infographic excel data pack, easy to analyze big data

Robust and transparent research methodology

Unmatched data quality and after sales service

Contact Us:

Global Insight Services LLC 16192, Coastal Highway, Lewes DE 19958 E-mail: info@globalinsightservices.com Phone: +1-833-761-1700 Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

[delicatemagazinedreamer]

Enzyme Linked Immunosorbent Assay Market Is Estimated To Witness High Growth Owing To Increasing Demand for Diagnostic Tests

The global Enzyme Linked Immunosorbent Assay (ELISA) market is estimated to be valued at US$ 2,016.1 million in 2022 and is expected to exhibit a CAGR of 5.1% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights. A) Market Overview: ELISA is a widely used laboratory technique used for detecting and quantifying proteins, antibodies, and hormones. It is used in various applications such as diagnostics, research, and quality control testing in pharmaceutical and biotechnology industries. The primary advantage of ELISA is its high sensitivity, specificity, and ability to process multiple samples simultaneously. The increasing demand for diagnostic tests owing to the rising prevalence of chronic diseases is driving the growth of the ELISA market. B) Market Key Trends: One key trend in the ELISA market is the growing adoption of ELISA in infectious disease testing. ELISA is extensively used for the detection of viral infections such as HIV, hepatitis, and dengue. Its ability to detect specific antibodies or antigens makes it an effective tool for diagnosing infectious diseases. For example, in the case of COVID-19, ELISA-based antibody tests have been used to determine the presence of antibodies against the SARS-CoV-2 virus and assess immunity levels in individuals. C) PEST Analysis: - Political: Government regulations and policies related to healthcare and diagnostics can impact the adoption and usage of ELISA tests. - Economic: The economic factors such as healthcare expenditure, insurance coverage, and disposable income of individuals influence the demand for ELISA tests. - Social: Increasing awareness about preventive healthcare and disease screening among the population is driving the demand for diagnostic tests like ELISA. - Technological: Advancements in technology have led to the development of automated ELISA systems, offering higher efficiency and accuracy in diagnostic testing. D) Key Takeaways: 1. Market size related content: The global Enzyme Linked Immunosorbent Assay Market Segmentation is expected to witness high growth, exhibiting a CAGR of 5.1% over the forecast period, due to increasing demand for diagnostic tests. The rising prevalence of chronic diseases and the need for early detection are driving the adoption of ELISA. 2. Regional analysis: North America is expected to be the fastest-growing and dominating region in the ELISA market. This can be attributed to the presence of advanced healthcare infrastructure, favorable government initiatives, and high healthcare expenditure in the region. 3. Key players: Key players operating in the global ELISA market include Bio-Rad Laboratories, Inc., Enzo Life Sciences, Inc., Thermo Fisher Scientific, Inc., Biomerieux S.A., Alpco, BioLegend, Inc., R&D Systems, Creative Diagnostics, Zeus Scientific, Inc., and Shenzhen YHLO Biotech Co., Ltd. These players focus on product development, collaborations, and strategic partnerships to gain a competitive edge in the market. In conclusion, the global ELISA market is set to experience significant growth driven by the increasing demand for diagnostic tests. The adoption of ELISA in infectious disease testing and advancements in technology are key trends shaping the market. Additionally, factors such as government regulations, economic conditions, social awareness, and technological advancements will influence the market's growth trajectory. The key players in the market are actively engaged in developing innovative products and forming strategic collaborations to cater to the growing demand for ELISA tests.

[rupalic]

New Revenue Sources in Insect Repellent Active Ingredients Market

Insect repellents are substances designed to deter insects from landing on the treated surface or contacting the skin. They are commonly used to prevent insect bites and the transmission of insect-borne diseases. There are several active ingredients found in insect repellent products, each with varying degrees of effectiveness and duration.

The insect repellent active ingredients market is estimated at USD 1.0 billion in 2023; it is projected to grow at a CAGR of 7.6% to reach USD 1.5 billion by 2028.

Some of the most common active ingredients in insect repellents include:

DEET (N,N-Diethyl-meta-toluamide): DEET is one of the most widely used and effective insect repellents. It can provide long-lasting protection against a variety of insects, including mosquitoes, ticks, and biting flies. DEET's effectiveness increases with higher concentrations, but concentrations above 50% don't necessarily provide significantly longer protection. DEET can be used on skin and clothing.

Picaridin (also known as Icaridin): Picaridin is another effective insect repellent that provides protection against mosquitoes, ticks, and other biting insects. It is less likely to damage synthetic materials, such as plastics and fabrics, compared to DEET. Picaridin is generally odorless, feels less greasy than DEET, and is considered a good alternative for people who prefer non-DEET options.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=111358884

Oil of Lemon Eucalyptus (OLE): Derived from the lemon eucalyptus plant, OLE is a natural insect repellent. The active ingredient in OLE is called PMD (para-menthane-3,8-diol), which has been shown to effectively repel mosquitoes. However, it's important to note that OLE is not recommended for children under three years old.

IR3535: This is an organic compound that works as an insect repellent against a variety of pests, including mosquitoes, ticks, and flies. It has a low odor and is considered safe for use on the skin.

Natural Extracts and Essential Oils: Some natural extracts and essential oils, such as citronella, lavender, cedarwood, and eucalyptus, are believed to have insect-repelling properties. While these can provide some level of protection, they tend to be less effective and have shorter durations compared to synthetic repellents like DEET and picaridin.

Asia Pacific is expected to account for the largest market share in 2023.

The insect repellent active ingredients market industry has been studied in North America, Europe, Asia Pacific, South America and Rest of the World. The Asia Pacific region is known for having a high prevalence of insect-borne diseases such as malaria, dengue fever, chikungunya, Japanese encephalitis, and Zika virus. According to article by National Library of Medicine 2022, India reported a ZIKV outbreak in Kerala in July 2021, the first activity in the region of South-East Asia since the outbreak in Rajasthan, India, in 2018. At least 70 ZIKV disease cases were found after extensive testing and confirmed by PCR by August 2021. These diseases pose significant health risks to the population, leading to a greater demand for insect repellent products and active ingredients to protect against insect bites. Major players operating in the insect repellent active ingredients market includes Spectrum Brands Inc. (US), Reckitt Beneckiser Group Plc (UK), Henkel AG & Co KGaA (Germany), MERCK KGaA (Germany), S.C. Johnson & Son Inc. (US), Dabur (India), Godrej (India), Sawyer (US), BUGG Products, LLC (US), Coghlan’s (Canada), Vertellus (US), Sumitomo Chemical Co., Ltd (Japan), Clariant (Switzerland), Citrefine (UK), NK Chemiosys Pvt. Ltd. (India), and Shorgun Organics (India).

Speak to the Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=111358884

DEET segment, by type, is expected to account for the largest share in 2023.

DEET has been proven to be highly effective in repelling a wide range of biting insects, including mosquitoes, ticks, flies, and fleas. It is known to provide long-lasting protection, making it a preferred choice for individuals seeking reliable insect repellent solutions. DEET can be used in various formulations, such as sprays, lotions, creams, and wipes, making it suitable for different user preferences and needs. It can be applied directly to the skin or on clothing, making it versatile for both personal and outdoor use.

[rohans18]

Viral Antigen Diagnostics Market Analysis and Forecast to 2028

Global Viral Antigen Diagnostics Market, By Diagnosis Test (Specimen Examination, Serodiagnostic Tests, Viral Isolation), Virus Type (Adenovirus, Cytomegalovirus, Dengue Virus, Enterovirus, Hepatitis Virus, HIV-1, Coronavirus, Human Metapneumovirus, Human Rhinovirus A, Measles Virus, Poliovirus, Rabies Virus, Varicella Zoster Virus, Avian Influenza, Coxsackievirus, Epstein-Barr Virus (EBV), Lymphocryptovirus, Herpes Virus (HSV-1, HSV-2), HIV-2, Human Herpesvirus, Human Papillomavirus (HPV), Influenza Virus, Mumps Virus, Rubella Virus, Respiratory Syncytial Virus (RSV), West Nile Virus), End User (Physician Offices, Commercial Laboratories, Nursing Homes), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028

The consistent Viral Antigen Diagnostics market report analyzes many points that help businesses to solve the toughest questions in less time. The major topics of this business report are global growth trends, market share by manufacturers, market size by type, market size by application, production by region, consumption by region, company profiles, market forecast, value chain and sales channels analysis, opportunities & challenges, threat and affecting factors. The report gives market definition in the form of market driving factors and market restraints which helps estimating the demand of particular product depending on several aspects. Viral Antigen Diagnostics market survey report studies the global market status and forecast, categorizes the global market size, market value & market volume by key players, type, application, and region.

Key Players

Cutera (U.S.)

LUTRONIC (South Korea)

Solta Medical (U.S.)

Venus Concept. (Canada)

Sciton (U.S.)

Cynosure LLC (U.S.)

Lynton Lasers Ltd (U.K.)

STRATA Skin Sciences (U.S.)

Lumenis Be Ltd. (U.S.)

Curallux, LLC (U.S.)

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-viral-antigen-diagnostics-market

One of the principal objectives of a high-ranking Viral Antigen Diagnostics industry report is to analyze and study the global sales, value, status, and forecast. The market report also analyzes the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. The report assists to define, describe and forecast the market by type, application and region. It estimates the region that is foretold to create the most number of opportunities in the global Viral Antigen Diagnostics market. This market research report comprises of estimations of CAGR values which are quite significant and aids businesses to decide upon the investment value over the time period. An insightful Viral Antigen Diagnostics market report assists clients to stay ahead of the time and competition.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Viral Antigen Diagnostics Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Sizing

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sales@databridgemarketresearch.com

[agadignostic1]

Point of Care Lab Testing: An Overview

POCT, also known as point-of-care testing, is the examination of patient specimens outside of the clinical laboratory, close to or at the site of patient treatment. POCT is typically carried out by healthcare professionals who have not had laboratory training, though it also includes patient self-monitoring. It has the ability to deliver a quick result close to the patient that can be used. The main motivator is the idea that sending samples to the clinical laboratory may cause a delay in clinical decision-making. Considerations of rising expenses for staff training, connecting to the laboratory information system (LIS), quality control (QC), and external quality assurance (EQA) procedures, all necessary for accreditation under ISO 22870, are weighed against this.

Being able to show that a quicker result (shorter turnaround times (TATs)) can leverage a clinically significant benefit in decision-making VS the central laboratory is necessary to justify POCT (CL).

Why is point of care lab testing gaining so much popularity?

The demand for accessible diagnosis, monitoring, and screening tests is growing globally as health care becomes more consumer-focused. In certain circumstances, technology has caught up; smaller, more portable, and simpler to use testing instruments have been created.

Between 2013 and 2018, the market for point-of-care testing is anticipated to expand by 9.3%. This pattern has a variety of causes. Point-of-care testing enables you and your physicians to make decisions about your medical care more quickly and, ideally, more effectively because results are provided in real time rather than over the course of several hours or days. You won't need to schedule a second appointment because you can start receiving follow-up testing or treatments right away with the results you obtain during your consultation.

As the focus of medical care turns to prevention, early detection, and the management of chronic illnesses, point-of-care testing is helpful. Early diagnosis in the emergency room can assist in determining whether patients with flu-like symptoms have the flu or a higher-risk virus like Middle Eastern Respiratory Syndrome (MERS). The fast strep test in the doctor's office enables early strep throat treatment and lowers the risk of consequences from delaying treatment. With the help of glucose metres, persons with diabetes can customise their insulin therapy at home. The market for point-of-care testing is dominated by it.

Rapid screening for infectious disorders like HIV, dengue fever, malaria, and influenza is also becoming more and more necessary. In rural locations with poor infrastructure for transporting samples or in community clinics with limited access to a central lab, infectious disease testing is helpful. Testing for infectious diseases at the point of care can also result in faster recovery and infection containment.

Benefits of POC testing

Point-of-care testing, when used correctly, can result in more effective, efficient medical treatments and higher-quality medical care. Point of care lab testing enables you to take charge of your medical care at home by enabling more frequent and reliable testing. The ideal outcome is higher-quality healthcare. For instance, research has indicated that patients who monitor blood thinners (anticoagulants) like warfarin themselves saw fewer severe side effects from the medication. Point-of-care testing can also deliver test findings in areas where clinical laboratories are absent or inaccessible, such as in underdeveloped nations, remote areas, on cruise liners, or even on the space shuttle.

Precautions to take while doing POC testing

Despite the fact that many point-of-care tests are made to be reasonably risk-free and easy to use, they are not error-proof. Even healthcare professionals who use point-of-care testing must carefully follow the test instructions and be conversant with the test system. If not carried out appropriately, certain point-of-care tests, such as those used to modify drug doses, could have detrimental effects on health. Point-of-care coordination teams are present in many large hospitals to guarantee adequate testing protocol adherence.

It's crucial that the ease of point-of-care testing does not lead users to utilize them for purposes other than what they were intended for or to interpret results incorrectly. For instance, glucose meters and point-of-care hemoglobin A1 tests are only meant to be used for diabetes monitoring and should not be utilized for screening or diagnosis. This needs to be understand while near patient testing.

An effective Covid-19 antibody assay has been created at AgPlus Diagnostics and work is being done on a Covid-19 antigen diagnostic. Being a recognised market leader in revolutionary Point of Care diagnostics and matching each patient's critical condition to the appropriate therapy at the appropriate time have always been the goals of our company.

[kenresearchcompany]

Global Immunoassays Market is expected to record a positive CAGR of ~6% during the forecast period 2022-2028: Ken Research

Immunoassays are bioanalytical techniques that use the precision of an antigen-antibody reaction to detect and quantify analytes in biological samples such as urine, blood, saliva, tissues, and cells. Clinical diagnostics, drug discovery, environmental monitoring, biopharmaceutical analysis, drug monitoring, and food testing are all common applications for such techniques. In addition, they generally exhibit quick and precise outcomes, allowing a clinician to diagnose a variety of diseases such as diabetes, cancer, and heart disease accurately.

The Global Immunoassays Market is expected to record a positive CAGR of ~6% during the forecast period (2022-2028) and reach a revenue of ~US$ 60 Bn by 2028, due to the rising prevalence of chronic and infectious diseases. The ongoing Covid-19 pandemic has accelerated the use of immune-diagnostics assays for correct diagnosis and containment of the Covid-19 pandemic. In addition, immunoassay tests are highlighted as an important diagnostic method as they enable reliable and affordable detection of viruses and bacteria. Such tests are used to detect both acute and chronic diseases.

For more information, request a free sample @ https://www.kenresearch.com/sample-report.php?Frmdetails=NTkyNDkz

The rising prevalence of chronic, and infectious diseases, including COVID-19, HIV/AIDS, dengue, foodborne disease, and other diseases is one of the major factors propelling the immunoassays market growth.

In addition, the cost-effectiveness and higher efficiency of immunoassay tests also make a significant contribution to their growth.

For instance, the WHO Pan American Health Organization (PAHO) reported 21,41,240 dengue cases in the Americas, including 10,53,420 confirmed cases and 927 associated deaths, as of August 2022. In addition, Brazil (19,10,657), Peru (57,469), Colombia (38,844), Nicaragua (37,369), and Ecuador have reported the most cases (12,645) during the same period.

In addition, according to the study conducted in 2021 by Food Security Cluster, an Italian non-profit organization that outlines food availability, access, and utilization issues, more than 600 million individuals (one in ten) globally, become ill with the foodborne disease each year, and 420,000 die.

Technical challenges with immunoassay kits/reagents and instruments are likely to impede the market growth.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak had been proclaimed a public health emergency in late January 2020, medical professionals and scientists experienced the necessity for extensive and rapid testing of individuals to implement measures to contain the virus's spread. Additionally, real-time PCR (RTPCR) tests and antibody/antigen tests have erupted as vital tools for the global healthcare system in managing the outbreak.

Key Trends by Market Segment

By Product Type:  Reagents & Kits hold the largest share of the Global Immunoassays Market in 2021.

Reagents/kits are a preferable type of product for immunoassay testing as they offer a quick, simple, and cost-effective method of detection with accuracy and specificity considerably better (in some cases) than other methods.

The global outbreak of Covid-19 has prompted governments to impose critical measures to prevent its spread, which focus primarily on accurate and prompt identification of virus-infected individuals using the most precise and sensitive method available, notably real-time reverse transcriptase PCR (RT-PCR). This has raised the global demand for detection kits.

For more information, request a free sample @ https://www.kenresearch.com/ask-customization.php?Frmdetails=NTkyNDkz

By Application: The infectious disease segment held the largest market share in 2021.

The rising global prevalence rate of infectious diseases such as HIV/AIDS, malaria, dengue fever, influenza, and Covid-19 is one of the major factors driving the demand for immunoassays tests for infectious diseases.

For instance, according to the world health organization (WHO), influenza leads to around 3 to 5 million serious cases and 250,000 to 500,000 deaths worldwide every year.

The growing number of cancer cases worldwide is also a significant contributor to the expansion of the immunoassay market during the forecast period.

For instance, according to the American Cancer Society, cancer continues to be the second leading cause of death in the U.S., after cardiovascular disease. In 2022, the U.S. is expected to see 1.9 million new cancer cases and 609,360 cancer deaths, for a total of 1,670 deaths per day.

By Technology: The Enzyme Immunoassays (EIA)/Enzyme-linked immunosorbent assays (ELISA) technology segment dominated the market for immunoassays in 2021.

This technology's accuracy and ability to provide quick results is a major driving factor. In addition, ELISA's simple procedure, high specificity and sensitivity, cost-effectiveness, and high efficiency are all contributing factors to its growth.

Furthermore, the use of ELISA/EIA for antigen/antibody detection is among the most commonly available diagnostic tools, and it is extensively used for diagnosing swine influenza as well.

According to the National Library of Medicine (NLM), operated by the U.S. federal government, ELISA, indirect fluorescence antibody (IFA), and virus neutralizing assays are used to detect porcine parainfluenza virus type-1 (PPIV-1) antibody in swine serum.

By End User: The Hospitals & Clinics segment account for the majority share of the Global Immunoassays Market in 2021.

The continuous development in the healthcare industry across countries has raised the requirement for hospitals with advanced techniques and facilities.

The growing number of infectious diseases tested during the assessments and processing of body fluids, particularly following the worldwide explosion of the Covid-19 pandemic, are other major factors influencing the demand for immunoassays tests in hospitals and clinics.

By Geography: North America accounts for the largest share among all Regions within the total Immunoassays market in 2021.

Increased technological adoption in diagnostic techniques, extensive research initiatives, and increasing government funding for point-of-care testing and regulatory science activities across the healthcare industry are all contributing factors to the growth of Immunoassays in North America.

For instance, in November 2021, the U.S. Department of Health and Human Services (HHS) announced a USD 650 million investment to enhance manufacturing capacity for fast, high-quality diagnostic testing via rapid point-of-care molecular tests that help in the detection of influenza, respiratory syncytial virus (RSV), and a cluster of respiratory viruses.

In October 2020, the National Institutes of Health announced the third round of contract awards for the intensity and manufacturing of new COVID-19 testing technologies in collaborative efforts with the Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services.

Additionally, the six new rapid acceleration of diagnostics (RADx) initiative contracts comprise USD 98.35 million for point-of-care and other novel testing techniques that provide modes of sample collection, processing, and output. Inclusion with smart devices, digital processing that can be deployed to COVID-19 hot spots, and test results readily accessible in minutes are among the advancements in such new techniques.

The Asia Pacific region is expected to grow at the fastest CAGR during the forecasted period 2022-2028, owing to the government's increased emphasis on improving healthcare infrastructure, the adoption of innovative laboratory techniques and procedures, such as blotting technique, and gel electrophoresis for quicker and more efficient examination and diagnosis of infectious and chronic diseases, and growing preference for diagnostic reagents.

To more regional trends, Ask for a Customization @ https://www.kenresearch.com/sample-report.php?Frmdetails=NTkyNDkz

Competitive Landscape

The Global Immunoassays market is highly competitive with ~500 players which include globally diversified players, regional players as well as a large number of country-niche players each with their niche bioanalytical setting such as clinical diagnostics, biopharmaceutical analysis, environmental monitoring, security, and food testing, and others, for end-users. The immunoassays market's growth is heavily reliant on detection technologies and advancements in testing equipment and instruments.

Country-Niche players constitute about ~75% of the competitors, while regional players constitute about ~20%. Some of the major players in the market include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Siemens Healthineers, Thermo Fisher Scientific, Danaher Corporation, PerkinElmer, Quidel Corporation, Ortho Clinical Diagnostics Holdings, Sysmex Corporation, DiaSorin S.p.A. and among others.

Recent Developments Related to Major Players and Organizations

In February 2022, Siemens Healthineers, a German healthcare company, launched Enhanced Liver Fibrosis (ELF) Test in the U.S., offering broad clinical access to the nonsurgical diagnostic tool. In addition, the Food and Drug Administration (FDA) granted De Novo marketing authorization for the test.

In July 2021, Roche, a Swiss pharmaceutical company, announced the launch of its new Elecsys Epstein-Barr virus (EBV) immunoassay panel, which includes the Elecsys EBV IgM, EBV VCA IgG, and EBV EBNA IgG immunoassays and detects Epstein-Barr virus antibodies at various infection stages.

In April 2021, DiaSorin, an Italian Biotechnology company, launched its new immunodiagnostic Point-of-Care (POC) reader 'LIAISON IQ' and the 'LIAISON Quick Detect Covid TrimericS Ab' test. The LIAISON IQ's test detects specific IgG antibodies against SARS-CoV-2 Spike Protein in human blood capillaries from a throat swab in 10 minutes.

In February 2021, Thermo Fisher Scientific Inc., a U.S.-based manufacturer of analytical laboratory instruments, announced a partnership with Mindray, a Chinese medical device company, to make two clinical chemistry analyzers available to customers in the United States (U.S.) and Canada for drug of abuse testing.

In April 2020, Bio-Rad Laboratories, a U.S.-based manufacturer of specialized technological products for the life science research and clinical diagnostics markets, announced the release of a blood-based immunoassay kit to detect antibodies to the coronavirus SARS-CoV-2, the virus associated with COVID-19. 

Conclusion

The Global Immunoassays Market is forecasted to continue steady growth that is witnessed since 2017. The market is primarily driven by the rising prevalence of chronic, and infectious diseases, including COVID-19. Though the market is highly competitive with over ~500 participants, few global players control the dominant share and regional players also hold a significant share.

Note: This is an upcoming/planned report, so the figures quoted here for market size estimate, forecast, growth, segment share and competitive landscape are based on initial findings and might vary slightly in the actual report. Also, any required customizations can be covered to the best feasible extent for Pre-booking clients and report delivered within maximum 2 working weeks.

Market Taxonomy

The Global Immunoassays Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 is segmented by Product Types, Application, Technology, and End-User. In addition, the report also covers the market size for each of the five regions' immunoassays markets. The revenue used to size and forecast the market for each segment is USD billion.

By Type            

Reagents & Kits

Analyzers/Instruments

Software & Services

By Application

Cardiology

Oncology

Autoimmune Diseases

Infectious Diseases

Others

By Technology

Radio immunoassay (RIA)

Enzyme Immunoassays (EIA) or Enzyme-linked immunosorbent assays (ELISA)

Fluoro Immunoassay (FIA)

Chemiluminescence Immunoassay (CLIA)

Others

By End User    

Hospital & Clinics

Clinical Laboratories

Pharmaceuticals & Biotech Companies

Blood Banks

Academic Research Centers

Others

By Geography

North America (U.S., Canada, Mexico)

Europe (Germany, UK, France, Italy, Spain, Rest of Europe)

Asia Pacific (China, Japan, India, Australia, South Korea, Rest of Asia Pacific)

Latin America, Middle East and Africa

[meditech-insights]

Global Nanopore Sequencing Market Valued at $200 Million in 2021, is expected to experience a substantial growth rate of 26% by 2026

Nanopore Sequencing, a fourth-generation sequencing technology, in which single strands of DNA or RNA are passed through tiny protein channel called as nanopore. These nanopores are embedded in an electrically resistant membrane that causes changes in the ion current, determining the sequence and modifications of bases.

The Global Nanopore Sequencing Market valued at $200 million (2021) is set to witness a significant growth rate of 26% in the next 5 years. Some of the main factors propelling the Global Nanopore Sequencing Market is the advantages of nanopore sequencing such as high throughput & ultra-long reads, technological developments in nanopore technologies, growing prevalence of infectious diseases, and rising investments in R&D.

Advantages of nanopore sequencing technology fuels the Nanopore Sequencing Market Demand

Over the years, there has been a substantial growth in the acceptance of nanopore sequencing for research as well as clinical applications because of significant advantages of nanopores such as label-free & ultralong reads and high throughput.

Some of the main advantages boosting its demand are:

Long-read sequencing: The ability to produce ultra-long reads of over 2 Mb is a major advantage of nanopore sequencing. Longer read lengths are more likely to cover full regions of repeated sequence and structural variation, allowing for a more comprehensive understanding of genetic variants and the reconstruction of complex genomes

Targeted sequencing: For nanopore sequencing, a variety of targeted sequencing approaches, such as targeted panels and whole exome enrichment, are available, leveraging both PCR- and hybrid capture-based targeted enrichment strategies

Rapid results: Unlike traditional sequencing approaches, which need analysis after sequencing is completed, nanopore sequencing allows for early insights to be gained as soon as the sequencing process begins

Low cost of sequencer: High-end sequencers from Illumina and PacBio are priced over $950k and $450k respectively which are too expensive as compared to the GridION nanopore-based sequencer offered by Oxford Nanopore Technologies at $49k

Increasing clinical applications: Nanopore sequencing is widely used for pathogen analysis such as outbreak surveillance of infectious diseases such as tuberculosis, Ebola, Zika, dengue fever, and Covid19, among others. Nanopore sequencing is also widely used by researchers and clinicians for cancer genomics and genetic disease diagnosis.

Explore Premium Report on Nanopore Sequencing Market @ https://meditechinsights.com/nanopore-sequencing-market/

Partnerships and acquisition to increase adoption and co-develop advanced solutions

The nanopore sequencing market has witnessed a number of partnerships and acquisition by market players to either improve the acceptance of this technology for clinical applications or to co-develop advanced sequencing platforms.

The following is a list of some of the strategic initiatives that boost the adoption of nanopore sequencing:

In April 2022, Oxford Nanopore Technologies collaborated with Genomics England to evaluate the benefits of sequencing for enhancing patient care and advancing research activities for the development of novel treatments on a larger scale using nanopore sequencing technology

In September 2021, Oxford Nanopore Technologies collaborated with Oracle to explore novel applications of genomic sequencing using the Oracle Cloud Infrastructure (OCI) to speed-up discovery of medical innovations

In August 2020, Oxford Nanopore Technologies entered into an agreement with the UK’s Department of Health and Social Care, to roll out its LamPORE SARS-CoV-2 tests at a number of NHS testing laboratories

In May 2020, F. Hoffmann-La Roche Ltd acquired Stratos Genomics, a US based fourth-generation genetic sequencing company, to advance the development of nanopore sequencer for diagnostic applications with the combination of electronics and biological components

Competitive Landscape Analysis of Nanopore Sequencing Market

The global nanopore sequencing market is marked by the presence of key players such as Oxford Nanopore Technologies (UK), Stratos Genomics, a Roche company (US), BaseClear B.V. (Netherlands), CD Genomics (US), and others.

For More Detailed Insights, Contact Us @ https://meditechinsights.com/contact-us/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com

info@meditechinsights.com

[kudos12]

Research Nester released a report titled “Dengue Testing Market: Global Demand Analysis & Opportunity Outlook 2030,” which delivers a detailed overview of the global dengue testing market in terms of market segmentation by test type, end-user, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The global dengue testing market is projected to grow with a moderate CAGR during the forecast period, i.e., 2022-2030, on account of the increasing occurrence of dengue virus infections, and the rise in adoption of cost-effective and reliable testing kits. In addition, the high prevalence of dengue infections results in growth in demand for dengue testing, which is projected to contribute majorly to the market growth. As per the World Health Organization statistics, the stated number of dengue virus infections surged from 505,430 in 2000 to greater than 2.4 million in 2010 and 5.2 million in 2019.

Download Sample of This Strategic Report @ https://www.researchnester.com/sample-request-3278

The market is segmented by test type into ELISA-based test, RT-PCR amplification assay, dengue IgG/IgM rapid test, and others. Among these segments, the ELISA-based test segment is anticipated to hold the largest share during the forecast period in the global dengue testing market ascribing to the rising adoption of this test by end-users owing to its higher sensitivity in diagnosing dengue. Additionally, on the basis of end-user, the diagnostic centers segment is expected to grow significantly, which can be credited to the higher preference of these centers for conducting dengue testing over other facilities.

On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, out of which the market in Asia Pacific is projected to hold the largest share throughout the forecast period owing to growth in government expenditure on developing healthcare facilities and the high prevalence of dengue-related infections in the region. The market in North America is also expected to grow significantly attributing to the significant research and development investments in the region, accompanied by the advancements in the healthcare infrastructure.

Get Exclusive Sample Copy of This Report @ https://www.researchnester.com/sample-request-3278

Increasing Occurrence of Dengue Virus Infections and Rise in Adoption of Cost-Effective and Reliable Testing Kits to Drive Market Growth

According to the World Health Organization, dengue is presently an endemic disease in greater than 100 countries. The Americas, South-East Asia and Western Pacific regions are worst affected due to dengue, with the Asian region representing 70% of the total dengue cases globally.

The global warming and extreme weather-related events caused due to major climate changes have aggravated the spread of dengue. This factor has raised the need for effective diagnostic tests to fulfill the healthcare necessities of the population in the regions affected. Additionally, coupled with the hike in the adoption of cost-effective and reliable testing kits are expected to boost the market growth in the upcoming years.

However, the unavailability of efficient dengue testing tools in lower-income countries and low per capita income of the population in these regions are some of the factors that are estimated to restrain market growth in the near future.

This report also provides the existing competitive scenario of some of the key players of the global dengue testing market, which includes company profiling of Abbott Laboratories, InBios International, Inc., EUROIMMUN AG, CERTEST BIOTEC SL, Abnova Corporation, ThermoFisher Scientific inc., F. Hoffmann-La Roche Ltd, Quest Diagnostics, DiaSorin Group, NovaTec Immundiagnostica GmbH, and others. The profiling enfolds key information of the companies, which encompasses business overview, products and services, key financials, and recent news and developments. On the whole, the report depicts detailed overview of the global dengue testing market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities, and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Curious about this latest version of report? Obtain Report Details @ https://www.researchnester.com/reports/dengue-testing-market/3278—————- Read More Market Related Reports——————— 

Hardware OTP Token Authentication Market Heparin Market Hydraulic Submersible Pumps Market Hydraulic Surgical Tables Market Hydroxychloroquine Sulphate Market

About Research Nester

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Contact Us

AJ Daniel Email: info@researchnester.com U.S. Phone: [+1 646 586 9123] U.K. Phone: [+44 203 608 591]

[market-research-future-pruthvi]

Diabetes Insulin Pen Market Size, Trends And Forecast To 2027

Africa Malaria Diagnosis & Treatment Market Overview

Malaria is a life-threatening disease that is transmitted through the bite of infected anopheles mosquitos. The infected mosquitos transmit the plasmodium parasite into the bloodstream of human body upon being bitten. As the parasite enters the human body, it travels around the body to affect the liver and matures with time. Upon attaining maturity, the parasite enters the bloodstream to infect the red blood cells in the body. This causes individuals suffering from malaria to frequently experience headache, vomiting, fever, and weakness.

The global malaria diagnostics market is anticipated to exhibit a CAGR of 4.6% during the assessment period between 2018 and 2023. It is reported in a study released by Market Research Future (MRFR), that the market is positively influenced by a number of factors. A major factor influencing this growth is the increasing advancements in technology related to diagnostic tools and the proliferating demand for such treatments in malaria-endemic countries. Other factors driving the market growth are rising support from the government in terms of investment funds and an increase in the collaboration between the research centers and the industry. Malaria diagnostic tests play a significant role in identifying malarial cases, which thereby boosts the growth of the overall malaria diagnostic market.

Africa Malaria Diagnosis & Treatment Market Segmentation

The global malaria diagnostics market segmentation is done as per technology and end-user.

By technology, the market is divided into microscopy, molecular diagnostic tests, malaria drugs cost and rapid diagnostic tests. Furthermore, the molecular diagnostic test is narrowed down into real-time polymerase chain reaction (RT-PCR) and polymerase chain reaction (PCR).

By end-users, the market comprises of clinics, hospitals, community healthcare, and others.

Africa Malaria Diagnosis & Treatment Market Regional Analysis

Geographically, the global malaria diagnostic market covers regions such as North America, European, Asia Pacific, and Middle East & Africa.

The North American region holds the largest share of the malaria diagnostic market and leads the global standings. The region is further expected to garner the largest market share during the forecast period 2018 and 2023. The market is slated for growth due to the rise in awareness, advancing medical technologies, favorable compensation setting for various surgical methods and procedures, medical tourism, and expanding growth of the healthcare sector.

Africa Malaria Diagnosis & Treatment Market Competitive Landscape

The global malaria diagnostics market comprises of a number of key and prominent players, including Leica Microsystems GmbH, Premier Medical Corporation Pvt. Ltd, Access Bio. Inc., Beckman Coulter Inc., bioMérieux, Nikon Corporation, Abbott Laboratories, Olympus Corporation, Sysmex Partec GmbH, Siemens Healthineers, and Bio-Rad Laboratories Inc.

March 28th, 2019, Global Health Innovative Technology Fund announced a total of 2.86 Billion Yen to aid 10 partnerships to research and develop new lifesaving drugs, diagnosis, and vaccines for disorders like Vaccines for Leishmaniasis and Malaria, Schistosomiasis, Malaria, Tuberculosis, Dengue, and Diagnostics.

Jan 2nd, 2019, ERADA Technology Alliance LTD, one of the leaders of innovative, rapid diagnostic solutions for early stage detection of infectious diseases, announced the launch of one of the world’s first diagnostic saliva test for malaria.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: info@marketresearchfuture.com

[herbalmedicine12]

Viral Antigens Market Business Research Details among the Top Manufacturers 2027

A virus can infect all types of life forms, from plants and animals to archaea and bacteria. A viral antigen is a poison or toxic substance administered by these virulent entities, which induces immune reaction in its host. For instance, a viral antigen is determined by IFA in neutrophils and platelets from bone marrow or blood or in serum, saliva, tears, or plasma by ELISA. Nucleic amplification tests can also be used to determine the stage of infection. The best outcomes are obtained when antigens are measured through blood tests or serum

A virus can infect all types of life forms, from plants and animals to archaea and bacteria. A virus antigen is a poison or toxic substance administered by a virus that induces an immune reaction in its host. A viral protein is an antigen identified by the viral genome that can be recognized through a particular immunological response. A viral antigen is determined by IFA in neutrophils and platelets from bone marrow or blood or in serum, saliva, tears, or plasma by ELISA. Nucleic amplification tests can also be used to determine the stage of infection. The best outcomes are obtained when antigens are measured through blood tests or serum.

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis – https://www.theinsightpartners.com/sample/TIPRE00017334/

Leading Viral Antigens Market Players:

Microbix     Biosystems

BIO-RAD     LABORATORIES INC.

Creative     Diagnostics

Aalto Bio     Reagents Ltd.

Advanced     Biotechnologies Inc.

Prospec-Tany     Technogene Ltd.

ACROBiosystems.

MERIDIAN     BIOSCIENCE, INC.

Rekom     Biotech S.L

LGC Limited

The report segments Global Viral Antigens Market as follows:

 By Component

Influenza     Viral Antigens

Coronavirus     Antigens

Zika     Virus Antigens

Ebola     Virus Antigens

Dengue     Virus Antigens

Herpes     Simplex Virus (HSV) Antigens

Rotavirus     Viral Antigens

Hepatitis     A-E Virus Antigens

Measles     Virus Antigens

Mumps/Parotitis     Virus Antigens

Others

By Technique

ELISA

Immunoassay

Hemagglutination

Radioimmunoassay     (RIA)

Immunoperoxidase     Staining

Immunofluorescence

Others

By End User

Hospitals

Clinics

Laboratories

Diagnostic     Centers

Blood     Banks

Research     Institutes

Products Insights In terms of component, the Coronavirus antigens segment held the largest share of the viral antigens market in 2019, and is expected to continue its dominance and register a higher the highest CAGR in the market during the forecast period. Application Insights Based on end user, the global viral antigens market is segmented into hospitals, clinics, laboratories, diagnostic centers, blood banks, and research institutes. The diagnostic centers segment held the largest share of the market in 2019, and the market for laboratories is expected to register grow at the highest CAGR during the forecast period.

Strategic Insights

Players operating in the viral antigens market adopt collaboration and partnership strategies to meet demands of end users through the introduction of technologically advanced offerings, and these strategies significantly support the growth of the market.

Immediate delivery of our off-the-shelf reports and pre booking of upcoming studies, through flexible and convenient payment methods – https://www.theinsightpartners.com/buy/TIPRE00017334/

Viral Antigens Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876

[ashwetu]

Meticulous Research® Unveils New Report: Africa IVD Market Poised to Reach $1.65 Billion by 2031

Meticulous Research®, a global leader in market research and consulting, has released a new report titled ‘Africa IVD Market Size, Share, Forecast & Trends Analysis by Offering, Technology (Immunoassay, PoC, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoCT), End User – Forecast to 2031.’ According to the latest findings, the Africa in vitro diagnostics (IVD) market is projected to grow at a compound annual growth rate (CAGR) of 3.1%, reaching $1.65 billion by 2031.

Download Sample Report Here : https://www.meticulousresearch.com/download-samplereport/cp_id=5415

Market Growth Drivers and Challenges

The expansion of the Africa IVD market is driven by multiple factors, including the rising prevalence of chronic and infectious diseases, increased investments from IVD companies, growing demand for point-of-care (PoC) and rapid diagnostics, and a burgeoning geriatric population. Furthermore, supportive government initiatives aimed at bolstering Africa's healthcare sector and increasing healthcare expenditure are playing a significant role in the market's development.

However, market growth is being restrained by the high costs of advanced IVD products, variations in test results for rapid diagnostics, and the stringent regulatory requirements for high-complexity diagnostic tests. On the other hand, advancements in genomics and proteomics, heightened awareness of early diagnosis, and the increasing adoption of personalized medicine are expected to create significant opportunities for market players. Despite these promising trends, uneven access to healthcare and a shortage of trained healthcare professionals remain critical challenges.

Check complete table of contents with list of table and figures:

Market Segmentation and Key Insights

The report provides detailed insights into the market, segmented by offering, technology, application, diagnostic approach, and end user:

By Offering: The market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment is expected to grow at the highest CAGR of 3.3% during the forecast period, driven by increased diagnostic test volumes for infectious diseases, particularly malaria and tuberculosis, and various initiatives aimed at improving healthcare access across Africa.

By Technology: In 2024, the immunoassay/immunochemistry segment is projected to account for the largest market share at 34.5%. This is largely due to immunoassay technology's efficient and accurate diagnostics for highly prevalent diseases such as HIV, malaria, and dengue in Africa, along with its cost-effectiveness and continuous development of new biomarkers.

By Application: The infectious diseases segment is expected to dominate the market in 2024, fueled by the widespread prevalence of diseases like COVID-19, dengue, and HIV. Increasing awareness of diagnostic testing and the availability of low-cost rapid test kits are key factors driving this segment’s growth.

Quick Buy:  https://www.meticulousresearch.com/Checkout/47708335

By Diagnostic Approach: Point-of-care testing (PoCT) is projected to witness the highest growth during the forecast period, driven by the rising demand for immediate diagnostic results, especially in remote and underserved regions.

By End User: Hospitals and clinics are expected to grow at the highest CAGR between 2024 and 2031. Factors such as the increasing number of hospitalizations for chronic diseases, rising healthcare expenditure, and the willingness of hospitals to adopt advanced diagnostic tools are contributing to this growth.

Geographic Insights

The report also provides an in-depth analysis of various African countries, including South Africa, Nigeria, Egypt, Algeria, Morocco, Kenya, Tunisia, Côte d’Ivoire, Tanzania, Cameroon, and the Rest of Africa. South Africa is projected to grow at the highest CAGR of 8.3% during the forecast period. The growth in South Africa is driven by increased healthcare expenditure, expanded access to diagnostic tools through partnerships and collaborations, and favorable government policies aimed at enhancing healthcare infrastructure.

Competitive Landscape

Key players in the Africa IVD market include Abbott Laboratories (U.S.), Becton, Dickinson and

Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche

Ltd (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo

Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China). These industry leaders continue to invest in the region, driving innovation and expanding their presence in the African market.

Request  Sample PDF Copy Here:  https://www.meticulousresearch.com/request-samplereport/cp_id=5415

Key Questions Addressed in the Report:

What is the current revenue generated by IVD products in Africa?

What are the projected growth rates for the Africa IVD market over the next 5–7 years?

What are the key drivers, opportunities, and challenges affecting this market?

Which market segments are generating the most traction in terms of offering, technology, and application?

Which countries in Africa offer significant growth opportunities for market participants? Who are the leading players, and what products and strategies are they employing in the Africa IVD market?

What recent developments are shaping the competitive landscape?

Contact Information

Meticulous Research®

Email: sales@meticulousresearch.com

Phone: +1-646-781-8004

LinkedIn: Connect with us

[industryinsights]

Zika Virus Testing Market Share, Size, Industry & Landscape Outlook, Revenue Growth Analysis to 2027

The worldwide Zika virus testing market share is anticipated to be driven by increasing Zika incidences around the globe. This virus was first detected in Rhesus monkeys in Uganda in 1947. Then, in 1952, humans were detected with the virus. Further investigations down the years led to the conclusion that Zika spreads through sexual contact (exchange of bodily fluids), blood transfusion, and from infected mothers to their children.

The virus was found to be a single-stranded RNA virus & transmitted through 2 Aedes species. These species also transmitted the Chikungunya and Dengue illnesses. The virus may also be perpendicularly transmitted during unsafe sex or perinatal period. During perinatal transmission, the virus passes from the mother to the fetus and leads to microcephaly or other fetal brain abnormalities.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5662

Hearing issues, improper growth, and eye problems are some of the common maladies resulting from Zika fetal infection. Nervous system disorders have also been found in patients suffering from Zika. But, the risk associated with the virus is greater among pregnant women. Some of the major indication of having contracted the virus are joint pains, rashes, fever, headache, muscle pain, etc.

Conjunctivitis has also been witnessed in some of the patients carrying the virus. Some of these signs may last for many days to weeks. Americas, Africa, and Asia Pacific are said to be the key regions experiencing the Zika virus epidemic. The implementation of the United States FDA proposals has resulted in containing the transmission of the virus. Effective health policies have also contributed to testing all blood products for Zika.

These efforts have jointly led to massive expansion of the global Zika virus testing industry. Considerable amounts of money spent by the United States government on research & development initiatives for the development of improved Zika testing procedures have assisted the market in gaining worldwide recognition. Projects taken up by sellers and manufacturers have driven the need for better Zika virus testing, boosting the industry revenues.

A lot of the demand for Zika screenings arise from Florida. The city is said to be home to many people experiencing symptoms akin to Zika. No awareness and wrong detection procedures are some of the hindrances in the market. The Zika virus testing market is divided on account of applications, tests, and geographies.

Segments - Further Insights

Various application sub-segments of the industry comprise hospitals, ambulatory centers, pathology laboratories, diagnostic centers, etc. The different screening tests include nucleic acid amplification and Zika virus antibody. Based on geographies, the market is classified on the basis of Europe, Asia Pacific, Americas, and the Middle East and Africa.

The steady transfer of Zika in Americas has led to the demand for effective screening services till the end of the forecast period. The continuous demand for the better identification & management of this illness should propel industry sales.

Eminent Players and Their Strategies

Well established participants in the global Zika virus testing market consist of ARUP Laboratories, Hologic, Luminex Corporation, Roche Molecular Systems, etc. They keep investing in newer technologies and regional growth to occupy more shares and spread their worldwide reach.

Access Report Details @ https://www.marketresearchfuture.com/upcoming-reports/zika-virus-testing-market-5662

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com